GO:0045342 MHC class II biosynthetic process: Biosynthesis Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0045342 describes the chemical reactions and pathways that result in the formation of major histocompatibility complex (MHC) class II proteins.
• MHC class II biosynthesis begins in the endoplasmic reticulum, where the alpha and beta chains assemble with the invariant chain (CD74) before trafficking through the endocytic route.
• The MHC class II transactivator CIITA is the master transcriptional regulator of MHC class II genes and is itself controlled by interferon-gamma and other signals.
• MHC class II molecules present exogenous peptides to CD4+ T cells, making this biosynthetic pathway central to adaptive immunity.
• Dysregulation of MHC class II biosynthesis is linked to autoimmune diseases such as celiac disease and to cancer immune evasion.
• CRISPR knockout, knock-in, and overexpression models enable precise dissection of MHC class II biosynthetic steps in human cells.
Description
MHC class II biosynthetic process (GO:0045342) is the set of chemical reactions and pathways that produce major histocompatibility complex class II proteins. These heterodimeric cell-surface glycoproteins are composed of an alpha chain and a beta chain and are expressed primarily on professional antigen-presenting cells, where they display processed exogenous peptides to CD4+ T lymphocytes. The biosynthetic route is distinct from that of MHC class I and intersects the endocytic pathway, allowing MHC class II molecules to sample peptides generated in endosomes and lysosomes. Understanding this process is fundamental to immunology because it determines the repertoire of antigens presented to helper T cells and shapes immune responses in infection, autoimmunity, and cancer. The formation of MHC class II molecules is tightly controlled at the transcriptional level. The MHC class II transactivator CIITA acts as a master regulator that coordinates expression of HLA-DR, HLA-DP, and HLA-DQ genes, and its activity is modulated by interferon-gamma and other immune signals. In addition, post-translational events, including assembly with the invariant chain CD74 and subsequent peptide loading, are essential for the biosynthetic pathway to yield functional MHC class II complexes. Defects or dysregulation at any of these steps can alter antigen presentation and contribute to disease. For researchers, GO:0045342 provides a framework to study how MHC class II molecules are synthesized, assembled, and transported. Experimental approaches such as CRISPR-based gene editing, transcriptomics, and proteomics can be used to dissect the roles of individual genes in this pathway. This article reviews the definition, mechanism, key genes, regulation, disease links, and research methods relevant to MHC class II biosynthetic process.
MHC class II biosynthetic process At A Glance
| GO ID | GO:0045342 |
|---|---|
| GO term | MHC class II biosynthetic process |
| Ontology | biological_process |
| Synonym | major histocompatibility complex class II biosynthesis; MHC class II anabolism; MHC class II biosynthesis; MHC class II formation; MHC class II synthesis |
| Major function | Production of MHC class II alpha/beta heterodimers that present exogenous peptides to CD4+ T cells |
| Cellular location | Endoplasmic reticulum, Golgi, endosomal compartments, and cell surface |
| Key regulator | CIITA (MHC class II transactivator) controls transcription of MHC class II genes |
| Pathway intersection | The MHC class II biosynthetic pathway intersects the endocytic route, unlike MHC class I |
What Is GO:0045342?
MHC class II biosynthetic process (GO:0045342) is defined as the chemical reactions and pathways resulting in the formation of major histocompatibility protein class II. It encompasses transcription of MHC class II genes, translation of the alpha and beta chains, assembly of the heterodimer with the invariant chain, and the intracellular trafficking steps that lead to a mature, peptide-loaded MHC class II molecule.
Why Is MHC class II biosynthetic process Important in Cell Biology?
MHC class II biosynthetic process is essential for adaptive immunity because it generates the molecules that present exogenous antigens to CD4+ T helper cells, thereby initiating and shaping immune responses. The pathway is also a central node in human disease: allelic variation in MHC class II genes influences susceptibility to autoimmune disorders, and altered expression of MHC class II molecules is observed in cancers and inflammatory conditions. Consequently, understanding how MHC class II molecules are synthesized and regulated provides mechanistic insight into immunity and offers targets for therapeutic intervention.
• MHC class II molecules are required for CD4+ T cell activation and helper T cell responses.
• The biosynthetic pathway intersects the endocytic route, enabling presentation of exogenous antigens.
• CIITA, the master transcriptional regulator, integrates immune signals such as interferon-gamma to control MHC class II expression.
• MHC class II genes are highly polymorphic and associated with autoimmune disease susceptibility.
• Post-translational modification of MHC class II-bound peptides can create neoepitopes relevant to celiac disease.
• MHC class II expression in tumors can influence immune surveillance and response to immunotherapy.
• Defects in MHC class II biosynthesis can impair antigen presentation and immune defense.
• The pathway is a target for experimental manipulation using CRISPR and other gene-editing tools.
What Happens During MHC class II biosynthetic process?
Transcriptional activation of MHC class II genes
In simple terms: First, the cell switches on the genes that code for MHC class II proteins.
The MHC class II biosynthetic process begins with transcription of the alpha and beta chain genes, primarily HLA-DR, HLA-DP, and HLA-DQ in humans. This transcription is controlled by the MHC class II transactivator CIITA, which is recruited to MHC class II promoters and is itself regulated by interferon-gamma and other immune signals. CIITA acts as a master regulator, and its expression determines whether a cell can synthesize MHC class II molecules.
Translation and assembly in the endoplasmic reticulum
In simple terms: The newly made protein chains are put together inside the cell's protein factory.
After transcription, the MHC class II alpha and beta chains are translated and inserted into the endoplasmic reticulum membrane. Here they assemble into a heterodimer and associate with the invariant chain (CD74), which prevents premature peptide binding and guides the complex through the secretory pathway. This assembly step is a critical part of the biosynthetic process and distinguishes MHC class II from MHC class I.
Trafficking through the endocytic route
In simple terms: The assembled MHC class II complex travels through the cell's recycling compartments.
The MHC class II-invariant chain complex moves from the endoplasmic reticulum through the Golgi and into endosomal compartments. The biosynthetic pathway of MHC class II, but not MHC class I, intersects the endocytic route, allowing the molecules to encounter peptides derived from exogenous antigens. This trafficking pattern is a defining feature of MHC class II biosynthesis and is essential for antigen presentation.
Peptide loading and surface expression
In simple terms: The MHC class II molecule picks up a peptide and moves to the cell surface to show it to immune cells.
In late endosomal compartments, the invariant chain is progressively degraded, leaving a class II-associated invariant chain peptide (CLIP) in the peptide-binding groove. CLIP is exchanged for high-affinity peptides derived from endocytosed antigens, a process facilitated by HLA-DM. The mature peptide-loaded MHC class II complex is then transported to the cell surface for presentation to CD4+ T cells. Post-translational modification of peptides can further influence this presentation, as seen in celiac disease.
Key Genes Involved in GO:0045342 MHC class II biosynthetic process
The following genes and proteins are central to the MHC class II biosynthetic process, from transcriptional control to peptide loading and surface presentation.
| Gene | Major Role | Research Relevance |
|---|---|---|
| HLA-DRA | Encodes the MHC class II alpha chain | Core structural component of the heterodimer; target for knockout and knock-in studies |
| HLA-DRB1 | Encodes the MHC class II beta chain | Highly polymorphic; associated with autoimmune disease risk |
| HLA-DPA1 | Encodes the DP alpha chain | Contributes to MHC class II diversity and antigen presentation |
| HLA-DPB1 | Encodes the DP beta chain | Polymorphic beta chain involved in peptide binding |
| HLA-DQA1 | Encodes the DQ alpha chain | Associated with celiac disease and other autoimmune conditions |
| HLA-DQB1 | Encodes the DQ beta chain | Key risk allele for celiac disease and type 1 diabetes |
| CIITA | Master transcriptional regulator of MHC class II genes | Central node for interferon-gamma responses; knockout abolishes MHC class II expression |
| CD74 | Invariant chain that associates with MHC class II | Required for proper assembly and trafficking; knockout alters peptide loading |
| HLA-DMA | Catalyzes peptide exchange on MHC class II | Facilitates CLIP removal and antigen loading |
| HLA-DMB | Enhances HLA-DM function | Modulates peptide repertoire presented by MHC class II |
| RFX5 | Transcription factor in MHC class II enhanceosome | Mutations cause bare lymphocyte syndrome; target for functional studies |
| RFXAP | Transcription factor in MHC class II enhanceosome | Required for CIITA-mediated activation |
| RFXANK | Transcription factor in MHC class II enhanceosome | Defects impair MHC class II transcription |
| NFYA | Transcription factor binding MHC class II promoters | Cooperates with CIITA for optimal expression |
| NFYB | Transcription factor binding MHC class II promoters | Part of the MHC class II enhanceosome |
| NFYC | Transcription factor binding MHC class II promoters | Part of the MHC class II enhanceosome |
| IFNGR1 | Interferon-gamma receptor subunit | Mediates IFN-gamma-induced MHC class II expression |
How Is MHC class II biosynthetic process Regulated?
MHC class II biosynthetic process is regulated primarily at the transcriptional level by the MHC class II transactivator CIITA, which is induced by interferon-gamma and other immune stimuli. CIITA acts as a coactivator that is recruited to MHC class II promoters through a multi-protein enhanceosome containing RFX5, RFXAP, RFXANK, and NF-Y subunits. In addition, post-translational events such as invariant chain degradation and peptide loading by HLA-DM modulate the final output of the pathway. In cancer, IFN-gamma can induce MHC class II expression with distinct patterns, indicating context-dependent regulation.
MHC class II biosynthetic process and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| HLA-DQB1 | Celiac disease, type 1 diabetes | Knock-in of risk alleles in intestinal organoids or cell lines |
| CIITA | Bare lymphocyte syndrome, cancer immune evasion | Knockout in antigen-presenting cells to abolish MHC class II expression |
| HLA-DRA | Autoimmunity, antigen presentation defects | Knockout and tagged knock-in for trafficking studies |
| CD74 | Impaired peptide loading, autoimmunity | Knockout to assess invariant chain function |
| HLA-DRB1 | Rheumatoid arthritis, multiple sclerosis | Point mutation of peptide-binding pocket residues |
Autoimmune and inflammatory diseases
MHC class II genes are among the strongest genetic risk factors for autoimmune diseases. Specific HLA-DQ and HLA-DR alleles are associated with celiac disease, type 1 diabetes, and rheumatoid arthritis, and the biosynthetic pathway determines which peptides are presented to autoreactive T cells. In celiac disease, post-translational modification of gluten peptides by transglutaminase creates neoepitopes that bind MHC class II molecules with high affinity, triggering an immune response.
Cancer immunology
MHC class II expression in tumors can influence immune surveillance and response to immunotherapy. In colorectal cancer organoids, IFN-gamma induces MHC class II expression with three distinct patterns, suggesting heterogeneity in antigen presentation capacity. Loss of MHC class II biosynthesis may contribute to immune evasion, making this pathway a potential biomarker and therapeutic target.
Primary immunodeficiency
Defects in the MHC class II biosynthetic pathway, such as mutations in CIITA or RFX genes, cause bare lymphocyte syndrome, a severe combined immunodeficiency characterized by absent MHC class II expression and impaired CD4+ T cell responses. This highlights the non-redundant role of the pathway in human immunity.
From MHC class II biosynthetic process-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of CIITA abolish MHC class II biosynthesis? | CRISPR knockout of CIITA in human cell lines |
| How does a disease-associated HLA-DQ variant alter peptide presentation? | Point mutation knock-in of the risk allele |
| Where does MHC class II traffic after assembly? | Tagged knock-in of HLA-DRA with fluorescent protein |
| Can overexpression of CIITA induce MHC class II in non-immune cells? | Overexpression of CIITA via lentiviral transduction |
| What is the role of CD74 in peptide loading? | Knockout of CD74 followed by immunoprecipitation and mass spectrometry |
| Does IFN-gamma induce distinct MHC class II expression patterns? | Organoid models treated with IFN-gamma and analyzed by flow cytometry |
How to Study the MHC class II biosynthetic process Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | mRNA levels of MHC class II genes and regulators | Profiling expression changes after IFN-gamma treatment |
| Flow cytometry | Surface MHC class II protein levels | Quantifying antigen-presenting cell phenotypes |
| Immunoprecipitation + mass spectrometry | Protein interactions and post-translational modifications | Identifying invariant chain and peptide cargo |
| Western blot | Total protein levels of MHC class II subunits | Validating knockout or overexpression efficiency |
| Fluorescence microscopy | Intracellular localization and trafficking | Tracking MHC class II from ER to endosomes |
| T cell activation assay | Functional antigen presentation | Measuring CD4+ T cell responses to specific peptides |
| CRISPR screening | Genes required for MHC class II biosynthesis | Unbiased discovery of pathway regulators |
| Proteomics | Global protein expression changes | Identifying co-regulated pathways in disease models |
Transcriptomic analysis
RNA sequencing (RNA-seq) can quantify mRNA levels of MHC class II genes (HLA-DRA, HLA-DRB1, HLA-DQA1, etc.) and CIITA under different conditions. This approach has been used to reveal IFN-gamma-induced expression patterns in colorectal cancer organoids.
Proteomic and immunochemical methods
Immunoprecipitation coupled with mass spectrometry can identify proteins associated with MHC class II complexes and characterize post-translational modifications. Western blotting and flow cytometry are standard for detecting MHC class II protein levels and surface expression.
Imaging of intracellular trafficking
Fluorescence microscopy and live-cell imaging of tagged MHC class II molecules allow visualization of their transport from the endoplasmic reticulum through endosomes to the plasma membrane, confirming intersection with the endocytic route.
Functional antigen presentation assays
T cell activation assays using MHC class II-restricted T cell hybridomas or primary CD4+ T cells measure the functional output of the biosynthetic pathway. These assays are complemented by peptide loading studies and HLA-DM activity measurements.
How CRISPR Can Be Used to Study GO:0045342 MHC class II biosynthetic process
Knockout
CRISPR knockout of CIITA, RFX genes, or MHC class II structural genes can completely abolish MHC class II biosynthesis, providing a clean background to study pathway requirements and downstream immune responses. Knockout of CD74 reveals its essential role in assembly and trafficking.
Point Mutation
Point mutations can be introduced into HLA-DQ or HLA-DR alleles to model disease-associated variants and dissect peptide-binding specificity. For example, mutating residues in the peptide-binding groove can alter antigen presentation and T cell activation.
Knock-in
Knock-in of fluorescent or epitope tags into endogenous HLA-DRA or HLA-DRB1 loci enables real-time tracking of MHC class II trafficking and assembly in live cells. Knock-in of disease-risk alleles into cell lines or organoids allows functional comparison.
Overexpression
Overexpression of CIITA or individual MHC class II chains can force expression in cells that normally lack MHC class II, such as cancer cells, to study antigen presentation and immune recognition. This approach has been used to induce MHC class II in non-immune cells and to test immunogenicity.
How EDITGENE Supports MHC class II biosynthetic process Research
Researchers studying MHC class II biosynthetic process-related genes often need to determine whether a candidate gene is causally involved in the pathway or is merely correlated with expression changes. CRISPR-based models provide a direct way to test gene function by creating loss-of-function, gain-of-function, or tagged alleles in relevant cell types.
Contact EDITGENE today to design your custom CRISPR model for MHC class II biosynthetic process research.
Frequently Asked Questions About MHC class II biosynthetic process
What is MHC class II biosynthetic process?
MHC class II biosynthetic process (GO:0045342) is the set of chemical reactions and pathways that produce major histocompatibility complex class II proteins, which present exogenous peptides to CD4+ T cells.
What genes are involved in MHC class II biosynthetic process?
Key genes include HLA-DRA, HLA-DRB1, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQB1, CIITA, CD74, HLA-DMA, HLA-DMB, and RFX transcription factors.
Where does MHC class II biosynthesis occur in the cell?
It begins in the endoplasmic reticulum, continues through the Golgi and endosomal compartments, and ends at the cell surface.
How is MHC class II biosynthesis regulated?
It is primarily regulated by the transcription factor CIITA, which is induced by interferon-gamma and cooperates with RFX and NF-Y factors.
What is the role of CIITA in MHC class II biosynthesis?
CIITA is the master transcriptional regulator that activates MHC class II gene expression in response to immune signals.
What diseases are associated with MHC class II biosynthesis?
Dysregulation is linked to autoimmune diseases such as celiac disease and type 1 diabetes, as well as cancer immune evasion and bare lymphocyte syndrome.
How can CRISPR be used to study MHC class II biosynthesis?
CRISPR knockout, knock-in, point mutation, and overexpression models allow functional dissection of MHC class II pathway genes in human cells.
What is the difference between MHC class I and MHC class II biosynthesis?
MHC class II biosynthesis intersects the endocytic route, whereas MHC class I biosynthesis does not, leading to presentation of exogenous versus endogenous antigens.
What methods are used to study MHC class II biosynthetic process?
Common methods include RNA-seq, flow cytometry, immunoprecipitation, mass spectrometry, fluorescence microscopy, and T cell activation assays.
Why is MHC class II biosynthetic process important for immunity?
It generates the molecules that present exogenous antigens to CD4+ T helper cells, which are essential for coordinating adaptive immune responses.
Conclusion
MHC class II biosynthetic process (GO:0045342) is a fundamental biological pathway that produces the antigen-presenting molecules required for CD4+ T cell activation. Its multistep nature, from CIITA-mediated transcription to peptide loading and surface expression, offers numerous points for experimental interrogation. Dysregulation of this pathway contributes to autoimmunity, immunodeficiency, and cancer, making it a high-value target for research and therapeutic development. Advances in CRISPR gene editing and functional genomics now allow precise manipulation of MHC class II pathway genes in relevant cell models. By combining knockout, knock-in, point mutation, and overexpression strategies with transcriptomic and proteomic readouts, researchers can uncover new mechanistic insights and identify candidate targets for intervention.
References
- 1. Neefjes J et al.. 2011. Towards a systems understanding of MHC class I and MHC class II antigen presentation.. Nat Rev Immunol 11(12):823-36 PMID: 22076556
- 2. Dendrou CA et al.. 2018. HLA variation and disease.. Nat Rev Immunol 18(5):325-339 PMID: 29292391
- 3. León Machado JA et al.. 2021. The MHC Class II Transactivator CIITA: Not (Quite) the Odd-One-Out Anymore among NLR Proteins.. Int J Mol Sci 22(3) PMID: 33499042
- 4. van den Elsen PJ et al.. 1998. Regulation of MHC class I and II gene transcription: differences and similarities.. Immunogenetics 48(3):208-21 PMID: 9683666
- 5. Sollid LM. 2017. The roles of MHC class II genes and post-translational modification in celiac disease.. Immunogenetics 69(8-9):605-616 PMID: 28695286
- 6. Neefjes JJ et al.. 1990. The biosynthetic pathway of MHC class II but not class I molecules intersects the endocytic route.. Cell 61(1):171-83 PMID: 2156628
- 8. Pickles OJ et al.. 2023. MHC Class II is Induced by IFNγ and Follows Three Distinct Patterns of Expression in Colorectal Cancer Organoids.. Cancer Res Commun 3(8):1501-1513 PMID: 37565053
